{"protocolSection":{"identificationModule":{"nctId":"NCT03861377","orgStudyIdInfo":{"id":"2019/376"},"secondaryIdInfos":[{"id":"2019-000961-19","type":"EUDRACT_NUMBER"}],"organization":{"fullName":"Helse Fonna","class":"OTHER"},"briefTitle":"Hemodynamics During Induction of General Anesthesia With Medium or Low Remifentanil Doses.","officialTitle":"\"Hemodynamic Stability During Induction of General Anesthesia With Propofol and Remifentanil: A Randomized, Controlled, Double-blind Study Comparing Medium and Low Remifentanil Doses.\"","acronym":"RH"},"statusModule":{"statusVerifiedDate":"2022-03","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2020-06-09","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2022-02-02","type":"ACTUAL"},"completionDateStruct":{"date":"2022-02-02","type":"ACTUAL"},"studyFirstSubmitDate":"2019-03-01","studyFirstSubmitQcDate":"2019-03-01","studyFirstPostDateStruct":{"date":"2019-03-04","type":"ACTUAL"},"lastUpdateSubmitDate":"2022-03-18","lastUpdatePostDateStruct":{"date":"2022-03-21","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"PRINCIPAL_INVESTIGATOR","investigatorFullName":"Gunnar Helge Sjøen","investigatorTitle":"Consultant in Anesthesiology","investigatorAffiliation":"Helse Fonna"},"leadSponsor":{"name":"Helse Fonna","class":"OTHER"}},"oversightModule":{"oversightHasDmc":false,"isFdaRegulatedDrug":false,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"In this trial the investigators want to examine if there is any difference in hemodynamic stability during induction when comparing two low and a medium remifentanil dose and keeping propofol induction dose at about 2.0 mg/kg.","detailedDescription":"Typically, one or more adjuvant medications is administered during induction of general anesthesia. When anesthetic drugs are combined, the hypnotic effects are often synergistic. Propofol is associated with hypotension and bradycardia and used together with remifentanil or sedative agents it may give synergistic or additive sedative and hemodynamic effects.\n\nRemifentanil is infused at 0.05-0.3 microg/kg/min during induction of anesthesia. Some use a loading dose of 0.5-1.0 microg/kg before starting the continuous infusion. The onset of action of remifentanil is within one to two minutes and it reaches rapidly a steady state effect site concentration after a bolus dose.\n\nKazmaier (2000) showed that a high-dose remifentanil anesthesia (2 microg/kg/min) reduced cardiac index (-25%), stroke volume (-14%) and mean arterial blood pressure (-39%) in a similar manner as propofol/remifentanil (propofol target 2 microg/ml and remifentanil 0.5 microg/kg/min), but systemic vascular resistance index decreased (-14%) in propofol/remifentanil combination. Fairfield et al have earlier (1991) showed that propofol 2.5 mg/kg induction without opioid reduces cardiac output (-15%) stroke volume (-5 %), mean arterial pressure (-33%) and systemic vascular resistance (-11%) and a slight reduction i heart rate. Guarracino (2003) suggests the reduction in cardiac index during induction with propofol/remifentanil with a low propofol target (1.2 microg/ml) may be due to decreased heart rate. Zaballos (2009) have shown that remifentanil depresses sinus node and atrioventricular (AV) -nodal function in comparison with propofol alone in a closed chest porcine model. Hayashi (2016) states that even in a low remifentanil effect site concentration (3.5 nanog/ml) it may reduce heart rate significantly when combined with propofol bolus 30-50 mg."},"conditionsModule":{"conditions":["Hemodynamic Instability","Anesthesia, General","Anesthesia, Intravenous"],"keywords":["Cardiac Output (CO)","Systolic Blood Pressure (SBP)","Systemic Vascular Resistance (SVR)","Heart Rate (HR)","Stroke Volume (SV)","Lithium Dilutional Cardiac Output (LiDCO)","Minimal Invasive Hemodynamic Monitor","Remifentanil"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE4"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","interventionModelDescription":"Randomized, controlled, double blind.","primaryPurpose":"BASIC_SCIENCE","maskingInfo":{"masking":"QUADRUPLE","maskingDescription":"Randomization made by a person not involved in trial in other ways. Allocation masked in sealed envelopes, stored in a locked cash box only opened by two drug preparing nurses not involved in patient care. Syringe labelled with patient identification (ID) (eg 03Remi). Patient, Care Provider and Investigator blinded for actual concentration of drug. Allocation break after data data wash and processing.","whoMasked":["PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":99,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Remifentanil R2","type":"ACTIVE_COMPARATOR","description":"Low dose Remifentanil induction dose (R2)","interventionNames":["Drug: Remifentanil R2"]},{"label":"Remifentanil R4","type":"ACTIVE_COMPARATOR","description":"Medium dose Remifentanil induction dose (R4)","interventionNames":["Drug: Remifentanil R4"]},{"label":"Remifentanil R8","type":"ACTIVE_COMPARATOR","description":"Medium dose Remifentanil induction dose (R8)","interventionNames":["Drug: Remifentanil R8"]}],"interventions":[{"type":"DRUG","name":"Remifentanil R2","description":"0,7 microg/kg","armGroupLabels":["Remifentanil R2"],"otherNames":["Ultiva"]},{"type":"DRUG","name":"Remifentanil R4","description":"1,1 microg/kg","armGroupLabels":["Remifentanil R4"],"otherNames":["Ultiva"]},{"type":"DRUG","name":"Remifentanil R8","description":"1,7 microg/kg","armGroupLabels":["Remifentanil R8"],"otherNames":["Ultiva"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Systolic Blood Pressure (SBP)","description":"Change in systolic blood pressure during induction","timeFrame":"First 7,5 minutes from start of induction"},{"measure":"Heart Rate (HR)","description":"Change in heart rate during induction","timeFrame":"First 7,5 minutes from start of induction"}],"secondaryOutcomes":[{"measure":"Stroke Volume (SV)","description":"Change in stroke volume during induction","timeFrame":"First 7,5 minutes from start of induction"},{"measure":"Cardiac Output (CO)","description":"Change in cardiac output during induction","timeFrame":"First 7,5 minutes from a start of induction"},{"measure":"Systemic Vascular Resistance (SVR)","description":"Change in systemic vascular resistance during induction","timeFrame":"First 7,5 minutes from start of induction"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Gynecological procedure\n* Age 18-50 years\n* General anesthesia planned\n* Systolic blood pressure \\< 150 mmHg, HR \\< 100 beats/min\n\nExclusion Criteria:\n\n* Pre-existing hypertension\n* Diabetes\n* Ischemic heart disease or cerebrovascular disease\n* Heart valve disease\n* Verified cardiac arrhythmia other than extrasystoles\n* Verified anaemia with hemoglobin level below 9.0 gr/dl.\n* Kidney or hepatic disease\n* Hypersensitivity for propofol, soya, eggs or peanuts\n* Pregnancy\n* Poor health state\n* Illicit substance use\n* BMI \\<20 or \\>35 kg/m2","healthyVolunteers":false,"sex":"FEMALE","minimumAge":"18 Years","maximumAge":"50 Years","stdAges":["ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Gunnar Sjøen, MD","affiliation":"Helse Fonna","role":"PRINCIPAL_INVESTIGATOR"}],"locations":[{"facility":"Kirurgisk Klinikk Anestesi","city":"Haugesund","state":"Rogaland","zip":"5504","country":"Norway","geoPoint":{"lat":59.41378,"lon":5.268}}]},"referencesModule":{"references":[{"pmid":"10844832","type":"BACKGROUND","citation":"Kazmaier S, Hanekop GG, Buhre W, Weyland A, Busch T, Radke OC, Zoelffel R, Sonntag H. Myocardial consequences of remifentanil in patients with coronary artery disease. Br J Anaesth. 2000 May;84(5):578-83. doi: 10.1093/bja/84.5.578."},{"pmid":"1751277","type":"BACKGROUND","citation":"Fairfield JE, Dritsas A, Beale RJ. Haemodynamic effects of propofol: induction with 2.5 mg kg-1. Br J Anaesth. 1991 Nov;67(5):618-20. doi: 10.1093/bja/67.5.618."},{"pmid":"12790210","type":"BACKGROUND","citation":"Guarracino F, Penzo D, De Cosmo D, Vardanega A, De Stefani R. Pharmacokinetic-based total intravenous anaesthesia using remifentanil and propofol for surgical myocardial revascularization. Eur J Anaesthesiol. 2003 May;20(5):385-90. doi: 10.1017/s0265021503000589."},{"pmid":"19457895","type":"BACKGROUND","citation":"Zaballos M, Jimeno C, Almendral J, Atienza F, Patino D, Valdes E, Navia J, Anadon MJ. Cardiac electrophysiological effects of remifentanil: study in a closed-chest porcine model. Br J Anaesth. 2009 Aug;103(2):191-8. doi: 10.1093/bja/aep131. Epub 2009 May 20."},{"pmid":"26462495","type":"BACKGROUND","citation":"Hayashi K, Tanaka A. Effect-site concentrations of remifentanil causing bradycardia in hypnotic and non-hypnotic patients. J Clin Monit Comput. 2016 Dec;30(6):919-924. doi: 10.1007/s10877-015-9794-4. Epub 2015 Oct 13."}]},"ipdSharingStatementModule":{"ipdSharing":"YES","description":"LiDCO-csv raw data and processed data will be made public at the publishers site, and the supporting information by request to the Principal Investigator. Statistical Data Plan is included in Study Protocol.","infoTypes":["STUDY_PROTOCOL","ICF","CSR"],"timeFrame":"The data will be stored for 15 years after end of study, and may be shared during this time frame.","accessCriteria":"The data may be shared by contacting the Principal Investigator."}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"browseLeaves":[{"id":"M21996","name":"Stroke","relevance":"LOW"},{"id":"M27273","name":"Systolic Murmurs","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC23","name":"Symptoms and General Pathology"}]},"interventionBrowseModule":{"meshes":[{"id":"D000077208","term":"Remifentanil"}],"ancestors":[{"id":"D000000701","term":"Analgesics, Opioid"},{"id":"D000009294","term":"Narcotics"},{"id":"D000002492","term":"Central Nervous System Depressants"},{"id":"D000045505","term":"Physiological Effects of Drugs"},{"id":"D000000700","term":"Analgesics"},{"id":"D000018689","term":"Sensory System Agents"},{"id":"D000018373","term":"Peripheral Nervous System Agents"}],"browseLeaves":[{"id":"M17997","name":"Propofol","relevance":"LOW"},{"id":"M18712","name":"Lithium Carbonate","relevance":"LOW"},{"id":"M3797","name":"Anesthetics","relevance":"LOW"},{"id":"M1696","name":"Remifentanil","asFound":"SARS-","relevance":"HIGH"},{"id":"M3722","name":"Analgesics","relevance":"LOW"},{"id":"M3723","name":"Analgesics, Opioid","relevance":"LOW"},{"id":"M11935","name":"Narcotics","relevance":"LOW"}],"browseBranches":[{"abbrev":"CNSDep","name":"Central Nervous System Depressants"},{"abbrev":"All","name":"All Drugs and Chemicals"},{"abbrev":"PsychDr","name":"Psychotropic Drugs"},{"abbrev":"Analg","name":"Analgesics"}]}},"hasResults":false}